Tag

Shukra Pharmaceuticals Limited

2 articles

Shukra Pharmaceuticals Q4 Net Loss of ₹1.73 Crore

Board approved audited standalone and consolidated financial results for Q4 and FY ending March 31, 2026, reporting a net loss of ₹1.73 crore for the quarter. Recommended a final dividend of ₹0.01 per

Shukra Pharmaceuticals Reports No Fund Utilization Deviation

Shukra Pharmaceuticals files SEBI Reg. 32(1) compliance disclosure confirming no deviation in utilization of ₹3.95 crore preferential issue proceeds. Company raised ₹3.95 crore as 25% consideration fo